

#DYK Did you know?

Cell & gene therapies are **rapidly advancing**, with projected **36%** annual growth through 2030



Over **1,500 drug candidates** in development from phase 0 to phase III studies



CAR-T therapies account for **32%** of the cell & gene therapy pipeline, focusing on haematological malignancies




Other cell therapies include **stem cell approaches** for regenerative medicine and cancer treatment




Gene therapies target **rare genetic disorders** like Duchenne Muscular Dystrophy and Sickle Cell Disease

CELL & GENE THERAPIES TRIALS:



3 DRUG CATEGORIES:



Trials grew **32.5%** from 2019 to 2023, with **over 1,000 unique trials**



Asia-Pacific leads in **faster patient recruitment**



US leads trials, followed by China, Europe, Japan and Australia



Oncology dominates, with **CAR-T and CAR-NK therapies** accounting for **~30%** of trials

China leads in CAR-T therapy, driven by regulations and lower costs

CAR-T and **CAR-NK** therapies advance in haematological and solid tumours

AI and CDMOs **transform personalized treatments and manufacturing** in cell & gene therapy

FDA approved 35+ therapies, with 10-20 new approvals expected annually by 2025

